Literature DB >> 3708631

Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes.

A Lichtenstein, J Berek.   

Abstract

The antitumor and immunological effects of a pyridine extractable fraction of Propionibacterium acnes were tested in a murine ovarian teratocarcinoma (MOT) model. Previous studies have demonstrated that tumor rejection in this model depends upon sequential activation of tumoricidal neutrophils (PMNs) followed by cytostatic macrophages. The pyridine extract significantly prolonged the survival of mice challenged with 10(3) or 10(4) MOT cells but had little impact on a 10(5) tumor inoculum. In vivo cytoreduction occurred within the first 24 h following IP treatment which correlated temporally with the influx of tumoricidal PMNs into the peritoneal cavity. Immunotherapy failure in mice challenged with 10(5) MOT cells occurred between 48 and 72 h after treatment when macrophage chemotaxis into the peritoneal cavity was initiated. Although injection of unfractionated bacteria activated MOT-cytostatic macrophages, the pyridine extract was deficient in this regard. Intraperitoneal injection of the pyridine extract resulted in an early (day +1) depression and late (day +5) enhancement of peritoneal NK cytotoxicity. These data suggest that the retention of neutrophil-activating moieties in the pyridine extract are sufficient for antitumor effects against low tumor inocula while the depletion of macrophage-activating determinants results in diminished effects against larger tumor cell challenges.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708631     DOI: 10.1007/bf00205712

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  Mechanisms of macrophage activation by Corynebacterium parvum. I. In vitro experiments.

Authors:  G H Christie; R Bomford
Journal:  Cell Immunol       Date:  1975-05       Impact factor: 4.868

2.  Studies on a transplantable teratoma of the mouse.

Authors:  E FEKETE; M A FERRIGNO
Journal:  Cancer Res       Date:  1952-06       Impact factor: 12.701

Review 3.  Corynebacterium parvum as an immunotherapeutic anticancer agent.

Authors:  M T Scott
Journal:  Semin Oncol       Date:  1974-12       Impact factor: 4.929

4.  Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.

Authors:  A K Lichtenstein; J Kahle; J Berek; J Zighelboim
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

5.  Augmentation of NK activity by Corynebacterium parvum fractions in vivo and in vitro.

Authors:  A Lichtenstein; A Bick; J Cantrell; J Zighelboim
Journal:  Int J Immunopharmacol       Date:  1983

6.  Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.

Authors:  C P Vanhaelen; R I Fisher
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

7.  Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.

Authors:  R C Bast; J S Berek; R Obrist; C T Griffiths; R S Berkowitz; N F Hacker; L Parker; L D Lagasse; R C Knapp
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

8.  Evidence for granulocyte-mediated macrophage activation after C. parvum immunization.

Authors:  S K Chapes; S Haskill
Journal:  Cell Immunol       Date:  1983-02-01       Impact factor: 4.868

9.  Rejection of murine ovarian cancer following treatment with regional immunotherapy: correlations with a neutrophil-mediated activation of cytostatic macrophages.

Authors:  A Lichtenstein
Journal:  Cell Immunol       Date:  1985-09       Impact factor: 4.868

10.  Use of a self-generating percoll gradient and single cell cytotoxicity assay to identify tumor-lytic properties of inflammatory neutrophils.

Authors:  A Lichtenstein; J Kahle; B Bonavida
Journal:  J Immunol Methods       Date:  1985-07-16       Impact factor: 2.303

View more
  2 in total

1.  Polyclonal activation of human lymphocytes by Bacillus firmus and its constituents.

Authors:  L Prokesová; J Julák; M Nováková; M Pospísil; M Mára
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

2.  Resistance to infection and activation of the monocyto-macrophage system caused by Bacillus firmus and its fractions.

Authors:  M Mára; J Ocenásková; M Nováková; J Julák; E Mencíková
Journal:  Folia Microbiol (Praha)       Date:  1994       Impact factor: 2.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.